Zentalis Pharmaceuticals, Inc. (ZNTL): restructuring charge — Zentalis restructures with 40% workforce cut, focuses WEE1 inhibitor, cash to late 2027

Zentalis Pharmaceuticals, Inc.

Approves workforce reduction of approx. 40%; substantially complete by Q2 2025.
Expects $7.0-8.0M in one-time termination costs in Q1 2025.
Believes cash runway extended into late 2027, beyond potential azenosertib data readout.
Registration-enabling DENALI Part 2 data readout anticipated by end of 2026.
Corporate event on Jan 29, 2025, to present azenosertib clinical data and regulatory update.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.4

Zentalis Pharmaceuticals, Inc. announced a restructuring with charges of approximately $7.0–8.0 million affecting the Company (approximately 40%).

Type: restructuring
Charge: approximately $7.0–8.0 million
Affected area: the Company
Headcount: approximately 40%

Exact text from the filing

On January 22, 2025, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc. (the “Company”) approved a strategic restructuring of the Company to support execution of late-stage development for the Company’s WEE1 inhibitor product candidate, azenosertib, and extend its cash runway beyond a potentially registration-enabling azenosertib data readout from the Company’s DENALI Part 2 study, anticipated by the end of 2026. In connection with this strategic restructuring, the Company expects to reduce its workforce by approximately 40%. The Company expects to incur one-time costs of approximately $7.0–8.0 million in the first quarter of 2025 in connection with the workforce reduction.

View on SEC.gov

13 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-25-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.